Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/24/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David B. Karpf MD

Wrong Dr. David B. Karpf MD?

Chief Medical Officer

Local Address: Menlo Park, California, United States
Virobay Inc
MENLO PARK, California 94025
United States

Company Description: Founded in 2006 as an anti-viral drug discovery and development company, Virobay was created to develop new treatments for hepatitis C infection based on small...   more

Employment History


  • M.D.
  • M.D. degree
    University of California , San Diego
  • MD
67 Total References
Web References
3. Virobay Appoints ..., 10 Nov 2011 [cached]
3. Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
ViroBay, 18 June 2013 [cached]
David B. Karpf MD Chief Medical Officer
David B. Karpf MD Chief Medical Officer
David B. Karpf has more than 20 years of experience in guiding the clinical development of novel therapeutics, both at growing biotechnology firms and within large pharmaceutical companies. David is responsible for all clinical, regulatory and medical affairs functions related to advancing Virobay's growing pipeline of novel product candidates.
Before joining Virobay, David served as Chief Medical Officer and Vice President, Clinical Affairs at Metabolex. At Metabolex, he oversaw the development of clinical programs in type 2 diabetes, dyslipidemia, and gout, including 2 INDs, 7 Phase 1 trials and 6 Phase 2 trials.
Prior to Metabolex, David was Executive Director of Clinical Research and Regulatory Affairs at Geron where he provided oversight for Geron's early clinical programs in cancer and regenerative medicine. Prior to Geron, David was Vice President, Clinical and Regulatory Affairs at Calydon, Inc. Prior to his tenure at Calydon, David was Executive Director of Clinical Research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease and endocrinology, including managing the Phase 3 pivotal program for Boniva™. David was previously Director of Clinical Research at Merck Research Laboratories in Rahway, New Jersey, where he played a pivotal role in the successful NDA and launch of Fosamax™.
In addition to his industry experience, David has held several academic positions and is currently an adjunct clinical professor of endocrinology with the Stanford University School of Medicine, where he directs one of the endocrine subspecialty clinics. He received his M.D. degree from University of California, San Diego, and served on the faculty at UCSF School of Medicine.
Metabolex, Inc. [cached]
February 9, 2004
Metabolex, Inc., a privately held pharmaceutical firm that discovers and develops drugs to treat diabetes and related metabolic diseases, today announced the appointment of David B. Karpf, M.D. as chief medical officer, effective January 30, 2004. Dr. Karpf joins Metabolex from Geron Corporation, where he served as executive medical director, clinical and regulatory affairs since 2001....
Medical & Scientific Advisory Board, 6 May 2014 [cached]
David Karpf picture
David Karpf, MD, President, Medical and Scientific Advisory
Dr. Karpf is an adjunct clinical professor of endocrinology at Stanford University School of Medicine, where he sees patients with osteoporosis and metabolic bone disease. He is board certified in internal medicine with a subspecialty in endocrinology and metabolism. A UC Berkeley graduate, Dr. Karpf received his medical degree from UC San Diego and completed residency in internal medicine and fellowship in endocrinology, diabetes and metabolism at UCLA/Cedars-Sinai Medical Center. This was followed by a fellowship in metabolic bone disease in the endocrine bone unit at UCSF, where his bench research focused on characterization and isolation of the PTH/PTHrP receptor.
In The News, 4 June 2008 [cached]
Dr. David B. Karpf, Chief Medical Officer of Metabolex and Clinical Associate Professor of Medicine at Stanford University School of Medicine, stated that to have a drug that addresses insulin resistance without causing the typically observed side effects of weight gain and edema, which should also predict a lower risk of congestive heart failure, would be a significant advance in the treatment of this common and often debilitating disease.
Other People with the name "Karpf":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.